Skip to content
Finance Investment, Oil Mining Resources

LTR Pharma Limited (ASX:LTP) – SPONTAN® Achieves Manufacturing Validation For Pivotal Clinical Study

LTR Pharma Limited (ASX:LTP) 2 mins read

• LTR Pharma has achieved manufacturing validation for its upcoming pivotal clinical study for its lead product, SPONTAN®.

• Essential criteria for a pivotal FDA clinical study have been met – including stability testing, quality control checks, product purity and packaging integrity.

• Patient recruitment for its bioequivalence study is due to commence this month.

LTR Pharma Limited (ASX:LTP) (“LTR Pharma”, “the Company”), a Company focused on improving men’s health through clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction (“ED”), SPONTAN®, is pleased to provide an update on the Company’s preparation for the product’s upcoming bioequivalence clinical study.

LTR Pharma, in conjunction with its Contract Manufacturing Organisation (CMO), has now successfully completed pivotal stability and quality control milestones for SPONTAN®. By testing the chemical stability of SPONTAN over three specified periods, whilst assessing packaging integrity and confirming purity of the active ingredients, LTR Pharma has now met key U.S. Food and Drug Administration (FDA) requirements to be considered a pivotal study.

Achieving this status signifies adherence to the highest product quality and regulatory standards and is an important step to support the start of clinical batch manufacturing and commencement of SPONTAN’s pivotal clinical study.

LTR Pharma Chairman, Lee Rodne, said: “This achievement has been underpinned by a comprehensive suite of quality control checks as mandated by the FDA. Each check was meticulously designed to evaluate the chemical stability of SPONTAN over specified time periods, assess the integrity of its packaging, and verify the purity of our nasal spray formulation. Completion of these critical steps signifies our Company’s commitment to adhering to the highest standards of product quality and regulatory compliance. We are optimistic about the potential impact of SPONTAN in the market and look forward to sharing our progress as we move closer to initiating the clinical trial.“

Patient recruitment for SPONTAN’s bioequivalence study is due to commence this month. The trial is a randomized, open-label, single-dose, two-treatment cross-over study that looks at how the body processes Vardenafil after giving it to 18 healthy adult men in the form of SONTAN Nasal Spray and Vardenafil Tablets.


About us:

LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma’s lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.


Contact details:

Jane Morgan

jm@janemorganmanagement.com.au

Media

More from this category

  • Business Company News, Finance Investment
  • 14/06/2024
  • 12:23
Jane Morgan Management

LTR Pharma Wins IPO of the Year Award, Celebrating Groundbreaking Advancements in Men’s Health

Sydney, Australia – 14 June 2024 – LTR Pharma, an ASX-listed company dedicated to improving men's health, is proud to announce be announced as the winner of the prestigious IPO of the Year Award. This accolade highlights the company's remarkable entry into the public market and its promising future in the healthcare sector. The Australian Stockbrokers Foundation award ceremony was held last night at the Sofitel Wentworth in Sydney and celebrated LTR Pharma's innovation and impact. Alpine Capital has been instrumental in this achievement, acting as the Lead Manager for LTR Pharma's successful IPO. Their expertise and strategic guidance have…

  • Industrial Relations, Oil Mining Resources
  • 13/06/2024
  • 14:57
Mining and Energy Union

Six-month lifeline for Eraring coal deal welcome but uncertainty remains

The Mining and Energy Unionwarns that workers at Myuna and Mandalong coal mines still face an uncertain future, despite a short-term deal struck between Origin Energy and Centennial Coal to keep supplying coal as part of a six-month extension. In May, the NSW Government and Origin reached an agreement to extend the operating life ofEraring Power Station until 2027. Northern Mining and NSW Energy District President Robin Williams said that while theMEU welcomed the announcement, workers would still find themselves in the same position in six months’ time. “Workers are hopeful that a longer-term arrangement can be reached considering that…

  • Employment Relations, Oil Mining Resources
  • 13/06/2024
  • 13:59
AWU

Court Hearing for Sibelco Silicosis Cases

The Australian Workers Union stands in solidarity with three of its members, Kevin Weekes, Craig Robertson, and Alan Jenkins, as their cases against former employer Sibelco are heard in Wonthaggi court tomorrow (14th of June 2024). These men, among many others, have been diagnosed with silicosis, a debilitating lung disease caused by prolonged exposure to silica dust in their workplaces. Call for Action and Legal Support The stories of Kevin, Craig, and Alan highlight the urgent need for stronger safety regulations and comprehensive support for workers affected by silicosis. Their struggle for justice represents a broader call to action for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.